S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Buy THIS stock before Taiwan is attacked (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Buy THIS stock before Taiwan is attacked (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Buy THIS stock before Taiwan is attacked (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Buy THIS stock before Taiwan is attacked (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
NYSE:AVNS

Avanos Medical - AVNS Competitors

$28.57
+0.58 (+2.07%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$27.64
$28.69
50-Day Range
$27.22
$31.75
52-Week Range
$19.32
$34.83
Volume
213,342 shs
Average Volume
256,298 shs
Market Capitalization
$1.33 billion
P/E Ratio
27.21
Dividend Yield
N/A
Price Target
$30.00

AVNS vs. ESTA, SMTI, ENOV, IOVA, RXRX, RDNT, PRCT, RCKT, EYE, and CINC

Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include Establishment Labs (ESTA), Sanara MedTech (SMTI), Enovis (ENOV), Iovance Biotherapeutics (IOVA), Recursion Pharmaceuticals (RXRX), RadNet (RDNT), PROCEPT BioRobotics (PRCT), Rocket Pharmaceuticals (RCKT), National Vision (EYE), and CinCor Pharma (CINC). These companies are all part of the "medical" sector.

Avanos Medical vs.

Establishment Labs (NASDAQ:ESTA) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Establishment Labs had 1 more articles in the media than Avanos Medical. MarketBeat recorded 5 mentions for Establishment Labs and 4 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.14 beat Establishment Labs' score of -0.38 indicating that Avanos Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Establishment Labs
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Avanos Medical
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Avanos Medical has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$161.70 million10.71-$75.21 million-$3.07-23.11
Avanos Medical$820 million1.62$50.50 million$1.0527.21

75.3% of Establishment Labs shares are owned by institutional investors. Comparatively, 92.1% of Avanos Medical shares are owned by institutional investors. 12.4% of Establishment Labs shares are owned by insiders. Comparatively, 2.1% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Avanos Medical has a net margin of 6.07% compared to Establishment Labs' net margin of -46.51%. Avanos Medical's return on equity of 6.13% beat Establishment Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Establishment Labs -46.51% -422.08% -32.53%
Avanos Medical 6.07% 6.13% 4.38%

Establishment Labs has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Establishment Labs presently has a consensus price target of $100.86, indicating a potential upside of 42.15%. Avanos Medical has a consensus price target of $30.00, indicating a potential upside of 5.01%. Given Establishment Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe Establishment Labs is more favorable than Avanos Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Establishment Labs
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Avanos Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Establishment Labs received 24 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 60.71% of users gave Establishment Labs an outperform vote while only 56.52% of users gave Avanos Medical an outperform vote.

CompanyUnderperformOutperform
Establishment LabsOutperform Votes
102
60.71%
Underperform Votes
66
39.29%
Avanos MedicalOutperform Votes
78
56.52%
Underperform Votes
60
43.48%

Summary

Establishment Labs and Avanos Medical tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVNS vs. The Competition

MetricAvanos MedicalSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$1.33B$6.84B$4.33B$14.09B
Dividend YieldN/A1.29%2.39%3.85%
P/E Ratio27.2123.00105.9919.99
Price / Sales1.6231.673,459.6410.36
Price / Cash10.9018.6927.2324.57
Price / Book1.033.104.466.79
Net Income$50.50M$118.97M$114.81M$870.19M
7 Day Performance2.88%0.55%-0.82%0.71%
1 Month Performance-0.31%-7.76%-6.59%-7.20%
1 Year Performance-12.15%-1.54%-16.59%-15.19%

Avanos Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESTA
Establishment Labs
1.8223 of 5 stars
$67.78
-3.8%
$100.86
+48.8%
+8.8%$1.66B$161.70M-22.08746
SMTI
Sanara MedTech
1.7253 of 5 stars
$39.90
-0.2%
$50.00
+25.3%
+34.5%$331.17M$24.14M-26.7840Analyst Revision
News Coverage
ENOV
Enovis
2.4794 of 5 stars
$50.10
-2.3%
$63.00
+25.7%
N/A$2.72B$1.56B-250.496,800High Trading Volume
IOVA
Iovance Biotherapeutics
2.5694 of 5 stars
$5.93
-5.7%
$18.20
+206.9%
-68.5%$1.33BN/A-2.39319Options Volume
News Coverage
RXRX
Recursion Pharmaceuticals
1.967 of 5 stars
$6.98
-6.1%
$12.80
+83.4%
-3.6%$1.33B$39.84M-5.09400
RDNT
RadNet
2.7366 of 5 stars
$23.28
-2.3%
$30.00
+28.9%
+3.3%$1.35B$1.43B136.949,067High Trading Volume
PRCT
PROCEPT BioRobotics
1.9863 of 5 stars
$30.20
-7.0%
$48.60
+60.9%
-16.9%$1.36B$75.01M-15.41234
RCKT
Rocket Pharmaceuticals
2.6466 of 5 stars
$17.13
-4.1%
$52.58
+207.0%
+4.1%$1.36BN/A-5.21151News Coverage
EYE
National Vision
2.8437 of 5 stars
$17.28
-2.6%
$32.00
+85.2%
-59.8%$1.37B$2.01B35.2713,975
CINC
CinCor Pharma
1.6839 of 5 stars
$29.06
-0.5%
$46.67
+60.6%
+66.8%$1.27BN/A-1.6815Upcoming Earnings
High Trading Volume
This page (NYSE:AVNS) was last updated on 3/25/2023 by MarketBeat.com Staff